S&P 500   2,904.71 (-2.49%)
DOW   25,039.00 (-2.82%)
QQQ   202.61 (-1.47%)
AAPL   268.02 (-2.01%)
MSFT   158.86 (+0.43%)
GOOGL   1,291.28 (-1.80%)
AMZN   1,853.02 (-1.66%)
CGC   18.00 (-2.39%)
BABA   200.56 (-2.18%)
GE   10.19 (-2.02%)
TSLA   643.10 (-5.29%)
AMD   44.41 (+0.91%)
F   6.81 (-2.44%)
GILD   68.52 (-5.70%)
DIS   115.15 (-2.45%)
S&P 500   2,904.71 (-2.49%)
DOW   25,039.00 (-2.82%)
QQQ   202.61 (-1.47%)
AAPL   268.02 (-2.01%)
MSFT   158.86 (+0.43%)
GOOGL   1,291.28 (-1.80%)
AMZN   1,853.02 (-1.66%)
CGC   18.00 (-2.39%)
BABA   200.56 (-2.18%)
GE   10.19 (-2.02%)
TSLA   643.10 (-5.29%)
AMD   44.41 (+0.91%)
F   6.81 (-2.44%)
GILD   68.52 (-5.70%)
DIS   115.15 (-2.45%)
S&P 500   2,904.71 (-2.49%)
DOW   25,039.00 (-2.82%)
QQQ   202.61 (-1.47%)
AAPL   268.02 (-2.01%)
MSFT   158.86 (+0.43%)
GOOGL   1,291.28 (-1.80%)
AMZN   1,853.02 (-1.66%)
CGC   18.00 (-2.39%)
BABA   200.56 (-2.18%)
GE   10.19 (-2.02%)
TSLA   643.10 (-5.29%)
AMD   44.41 (+0.91%)
F   6.81 (-2.44%)
GILD   68.52 (-5.70%)
DIS   115.15 (-2.45%)
S&P 500   2,904.71 (-2.49%)
DOW   25,039.00 (-2.82%)
QQQ   202.61 (-1.47%)
AAPL   268.02 (-2.01%)
MSFT   158.86 (+0.43%)
GOOGL   1,291.28 (-1.80%)
AMZN   1,853.02 (-1.66%)
CGC   18.00 (-2.39%)
BABA   200.56 (-2.18%)
GE   10.19 (-2.02%)
TSLA   643.10 (-5.29%)
AMD   44.41 (+0.91%)
F   6.81 (-2.44%)
GILD   68.52 (-5.70%)
DIS   115.15 (-2.45%)
Log in

OTCMKTS:GNMSF - Genmab A/S Stock Price, Forecast & News

$232.50
-7.50 (-3.13 %)
(As of 02/28/2020 11:28 AM ET)
Today's Range
$232.50
Now: $232.50
$237.50
50-Day Range
$216.44
MA: $233.00
$250.15
52-Week Range
$160.80
Now: $232.50
$250.15
Volume212 shs
Average Volume835 shs
Market Capitalization$14.34 billion
P/E Ratio46.13
Dividend YieldN/A
Beta0.26
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNMSF
CUSIPN/A
CIKN/A
Phone45-7020-2728

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$804.57 million
Cash Flow$5.43 per share
Book Value$34.13 per share

Profitability

Net Income$324.68 million

Miscellaneous

Employees377
Market Cap$14.34 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.


Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.02. The company earned $45.65 million during the quarter, compared to analyst estimates of $53.94 million. Genmab A/S had a return on equity of 19.95% and a net margin of 40.23%. View Genmab A/S's Earnings History.

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Genmab A/S.

Has Genmab A/S been receiving favorable news coverage?

Press coverage about GNMSF stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Genmab A/S earned a news impact score of -4.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Genmab A/S.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the folowing people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
  • Ms. Jane Juel, Sr. Director of Operations & Resource Management
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $232.50.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $14.34 billion and generates $804.57 million in revenue each year. Genmab A/S employs 377 workers across the globe.View Additional Information About Genmab A/S.

What is Genmab A/S's official website?

The official website for Genmab A/S is http://www.genmab.com/.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel